At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 148 enrolled
Drug / intervention
MEDI3506 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI3506 in Adult Subjects With Moderate-to-severe Atopic Dermatitis
In Brief
A Phase 2 clinical trial evaluating MEDI3506 and Placebo for Atopic Dermatitis. Completed, enrolled 148 participants across 38 sites in 6 countries.
Detailed Summary
This is a research study to determine the efficacy and safety of investigational drug MEDI3506 for the treatment of adult subjects with Atopic Dermatitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesAustralia, Germany, Poland, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
Enrollment StartDec 2019
First PostedDec 2019
Primary CompletionJul 2022
Study CompletionSep 2022
TodayJul 2026
First PostedDec 26, 2019
Enrollment StartDec 9, 2019
Primary CompletionJul 21, 2022
Study CompletionSep 20, 2022
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 6.5 years ago
Interventions
MEDI3506drug
multiple doses
Placebodrug
multiple doses